Wysa
FDA Breakthrough-designated AI mental health companion delivering CBT support across 95 countries, 24/7
Overview
Wysa is a clinically validated, AI-powered mental health chatbot that delivers evidence-based cognitive behavioural therapy (CBT), dialectical behaviour therapy (DBT), and mindfulness tools via a conversational interface on iOS and Android. Founded in 2015 in Bangalore by Jo Aggarwal and Ramakant Vempati, the platform received FDA Breakthrough Device Designation in May 2022 for its AI-led conversational agent targeting chronic musculoskeletal pain co-occurring with depression and anxiety. As of 2026, it has served more than 6 million people across 95 countries with over 550 million conversations, and is deployed across 31 NHS Talking Therapies services in the UK — where 117,000+ patients have used its Digital Referral Assistant since 2022.
Beyond its consumer freemium app, Wysa operates an enterprise business (Wysa for Enterprise, Wysa Assure, and the Wysa Copilot hybrid human-AI platform launched November 2024) used by insurers, health systems, and employers. MassMutual became the first US insurer to offer Wysa Assure to policyowners in October 2024, co-developed with Swiss Re. In 2025, Wysa expanded aggressively into the US market by acquiring behavioural health provider April Health (March 2025) and physical therapy company Kins (September 2025), positioning itself as a mind-body integrated care platform. Wysa also received a USD 3.4 million NIH grant in 2025 for personalised mental health support for chronic pain.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 4 Sep 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Unlimited AI chat
- Mood tracking
- Basic exercise library
- 150+ guided exercises
- Sleep & anxiety programs
- Progress tracking
- Text-based coaching sessions
- Personalized care plan
Use cases
What you can produce with Wysa
- Daily mood tracking with PHQ-9 and GAD-7 aligned outcome measurement
- 150+ guided CBT, DBT, and mindfulness exercises accessible in-app
- AI-driven crisis detection with escalation routing to human support
- Wysa Copilot dashboard for therapists to prescribe tools and monitor patient progress between sessions
- Enterprise anonymised population analytics for HR and clinical teams
- Automated patient intake and self-referral workflow for health systems (Digital Referral Assistant)
- Multilingual support including English, Spanish, Hindi, Marathi and additional Indian regional languages
ASEAN Perspective
Wysa in Southeast Asia
Wysa has genuine roots in South Asia — founded in Bangalore, with multilingual support that includes Hindi, Marathi, and other Indian regional languages, and a Singapore national health cluster pilot during COVID-19 (2020–2022). However, dedicated localisation for Southeast Asian markets (Bahasa Indonesia, Filipino, Thai, Vietnamese) remains limited, and regional enterprise pricing has not been publicly disclosed, making B2B adoption in ASEAN health systems uncertain. The platform's recognition at the India AI Impact Summit 2026 reinforces its APAC credibility, but ASEAN users outside India and Singapore will find both language coverage and local clinical partnerships thinner than in the UK or US markets.
An FDA Breakthrough Device Designation from May 2022 puts Wysa in rare company among consumer mental-health apps — regulatory validation, not just wellness-app marketing. NHS data backs it up: 31 Talking Therapies services, 117,000+ patients through its Digital Referral Assistant since 2022, a 91% self-referral completion rate, and clinicians saving roughly 21 minutes per assessment.
2025 was an acquisition year — April Health in March, Kins in September — moving Wysa from standalone chatbot toward integrated mind-body care, backed by a $3.4M NIH grant. MassMutual became the first US insurer to offer Wysa Assure to policyholders in October 2024.
The gaps: this isn't therapy, and Wysa says so — it's built for mild-to-moderate symptoms, with free-tier session caps that can frustrate someone in acute distress. Premium runs roughly $30/month, a real cost barrier across much of ASEAN, and the enterprise API is closed, sold only through custom contracts.
What people say
117,000 patients and counting: that's how many people have gone through Wysa's Digital Referral Assistant inside NHS Talking Therapies since 2022, across 31 services, with self-referral completion up to 91% (a 25-point jump) and clinicians saving about 21 minutes per assessment. That's the kind of operational data that's hard to fake, and it's a big part of why Wysa gets taken seriously by health systems rather than dismissed as another wellness app.
The clinical backing runs deeper than the NHS numbers — an FDA Breakthrough Device Designation from 2022, more than 45 peer-reviewed publications, and outcome studies that put chronic-pain and anxiety results in the same range as in-person counseling. On the consumer side, the free tier covers real ground: unlimited AI chat, mood tracking, and a chunk of the exercise library, though app-store and Reddit reviews flag the paywall as the sorest point — a recurring complaint is not wanting to pay roughly $75 a year just to unlock guided meditation.
2025 pushed Wysa past the standalone-chatbot phase: acquisitions of April Health (March) and Kins (September) built out a mind-body care model, and MassMutual made Wysa Assure available to US policyholders in October 2024, the first time a major US insurer offered anything like it. The honest caveat — Wysa states it plainly — is that this isn't a substitute for a licensed therapist, and it's positioned for mild-to-moderate symptoms rather than crisis-level care.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Wysa's AI penguin mascot was deliberately designed to feel non-threatening — early user research found people disclosed more to an animal persona than to a human avatar.
- Over 91% of patients who used Wysa's NHS Digital Referral Assistant completed their self-referral — a 25-percentage-point improvement over previous baseline rates.
- Wysa received its FDA Breakthrough Device Designation in May 2022, making it one of the first AI mental health chatbots to reach that regulatory milestone.
- Swiss Re co-created Wysa Assure specifically as an insurance-embedded mental health product — a first-of-kind model that MassMutual adopted in October 2024.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Wysa's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Wysa unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Wysa directly →
Spotted something out of date? Suggest an update →
More in Healthcare
